NCT04701203 - A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

January 12, 2022

Study Completion Date

January 21, 2025

Conditions

HypoparathyroidismEndocrine System DiseasesParathyroid Diseases

Interventions

COMBINATION_PRODUCT

TransCon PTH

TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.

COMBINATION_PRODUCT

Placebo

Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.

Trial Locations (21)

1083

Ascendis Pharma Investigational Site, Budapest

2100

Ascendis Pharma Investigational Site, Copenhagen

6720

Ascendis Pharma Investigational Site, Szeged

8200

Ascendis Pharma Investigational Site, Aarhus

10032

Ascendis Pharma Investigational Site, New York

27834

Ascendis Pharma Investigational Site, Greenville

40138

Ascendis Pharma Investigational Site, Bologna

55905

Ascendis Pharma Investigational Site, Rochester

56126

Ascendis Pharma Investigational Site, Pisa

60637

Ascendis Pharma Investigational Site, Chicago

76132

Ascendis Pharma Investigational Site, Fort Worth

78731

Ascendis Pharma Investigational Site, Austin

89511

Ascendis Pharma Investigational Site, Reno

94143

Ascendis Pharma Investigational Site, San Francisco

99204

Ascendis Pharma Investigational Site, Spokane

B3H 2Y9

Ascendis Pharma Investigational Site, Halifax

L6M 1M1

Ascendis Pharma Investigational Site, Oakville

G1V 4G2

Ascendis Pharma Investigational Site, Québec

01307

Ascendis Pharma Investigational Site, Dresden

00128

Ascendis Pharma Investigational Site, Rome

0176

Ascendis Pharma Investigational Site, Oslo

All Listed Sponsors

lead

Ascendis Pharma Bone Diseases A/S

INDUSTRY